Your Search Results

Optimising CTO outcomes by lesion selection

21 May 2025 – From EuroPCR 2025

Optimize chronic total occlusion (CTO) PCI outcomes through lesion selection strategies. This session reviews coronary calcium patterns via CT, target vessel considerations, distal vessel remodeling, imaging-guided versus conventional approaches, and complex lesion cases.

Optimising CTO outcomes by lesion selection

A simple low profile solution to the pulmonary embolism problem: EKOS

21 May 2025 – From EuroPCR 2025

Discover a streamlined approach to pulmonary embolism treatment in this EuroPCR 2025 session. Learn how ultrasound-assisted thrombolysis improves right ventricular function and pulmonary perfusion while enabling timely reperfusion with low-dose thrombolytic therapy delivered directly to the clot. Explore the latest data from the HI-PEITHO randomised trial...

TAVI in patients with a small annulus

20 May 2025 – From EuroPCR 2025

Address the unique challenges of transcatheter aortic valve implantation (TAVI) in patients with small aortic annuli. This session discusses comparative outcomes of balloon-expandable versus self-expandable valves, size prediction methodologies, and management of paravalvular regurgitation in low-flow, low-gradient aortic stenosis cases.

Left main bifurcation - LIVE Case

30 Jan 2026 – From SASCI-AfricaPCR

Join this session if you want to understand and optimise treatment strategies for LM bifurcation lesions, specifically: Understanding LM bifurcation anatomy and physiology, choosing the best stent strategy, optimising stent deployment and results.

LIVE Case from Groote Schuur Hospital Cape Town

Calcified lesions - LIVE Case

30 Jan 2026 – From SASCI-AfricaPCR

Watch this session if you want to understand the challenges and risks when treating calcified lesions, to learn how to accurately assess coronary calcification, to learn how to utilise the tools available for treating calcified lesions.

LIVE Case from Groote Schuur Hospital Cape Town

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author

Alessandro Sticchi

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...